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James L Turvill, Daniel Turnock, Dan Cottingham, Monica Haritakis, Laura Jeffery, Annabelle Girdwood, 
Tom Hearfield, Alex Mitchell and Ada Keding
The Fast Track FIT study:
diagnostic accuracy of faecal immunochemical test for haemoglobin in 
patients with suspected colorectal cancer
INTRODUCTION
The National Institute for Health and Care 
Excellence (NICE) has issued guidance to help 
GPs identify those patients at increased risk 
of colorectal cancer (CRC) (NICE guideline 12 
[NG12]).1 These recommendations are 
largely symptom-based, modified by age. The 
guidance is underpinned by a ‘2-week wait’ 
referral pathway to secondary care and other 
national targets for timeliness in treatment.2 
Delivering these diagnostic and treatment 
targets has proven very challenging for 
secondary care providers.3–6 There has been 
a yearly increase in ‘2-week wait’ referrals of 
patients with suspected CRC, but despite this, 
the number of CRC cases detected through 
this pathway has changed little.7 Since the 
prevalence of CRC in this cohort of patients 
is 3%–5%, large numbers of often older and 
frail patients undergo unnecessary, invasive, 
unpleasant, and expensive investigations, 
which are not without risk of complication.8 
Because investigative capacity (notably 
colonoscopy and computed tomography 
[CT] scans) is constrained, the investigative 
burden placed on secondary care by NG12 
has had the indirect effect of limiting the 
availability of investigative resource to support 
other CRC diagnostic pathways.9–11 
Faecal immunochemical test (FIT), a 
quantitative test for human haemoglobin 
in faeces, has been recommended to guide 
referral of patients who are considered to 
be at ‘low risk’ of CRC.12–14 A FIT ≥10 µg 
Hb/g faeces escalates the patient into the 
‘2-week wait’ pathway. FIT is also used in 
the bowel cancer screening programme 
(BCSP) where the cut-off value is set 
higher, at 120 µg Hb/g faeces.15 There is 
increasing interest in whether FIT has a role 
in decision making for all patients fulfilling 
NG12 criteria. It has been postulated in 
previous studies that FIT might refine and 
improve the diagnostic pathway for CRC 
in these patients. Initial studies suggested 
that FIT has a sensitivity and specificity of 
84.6% and 88.5%, respectively, for CRC in 
the context of patients fulfilling the NG12 
referral guidance.16 
A diagnostic accuracy study of FIT in 
patients referred through the ‘2-week 
wait’ pathway with suspected CRC was 
undertaken. FIT was provided before 
secondary care investigation and assessed 
against final diagnosis for CRC (primary 
outcome) and for significant premalignant 
polyps, inflammatory bowel disease 
(IBD), and other organic enteric disease 
(OED) combined (secondary outcomes). 
Abstract
Background
The faecal immunochemical test (FIT) is now 
available to support clinicians in the assessment 
of patients at low risk of colorectal cancer 
(CRC) and within the bowel cancer screening 
programme. 
Aim
To determine the diagnostic accuracy of FIT for 
CRC and clinically significant disease in patients 
referred as they were judged by their GP to fulfil 
National Institute for Health and Care Excellence 
guideline 12 (NG12) criteria for suspected CRC.
Design and setting
Patients referred from primary care with 
suspected CRC, meeting NG12 criteria, to 
12 secondary care providers in Yorkshire and 
Humber were asked to complete a FIT before 
investigation.
Method
The diagnostic accuracy of FIT based on final 
diagnosis was evaluated using receiver operating 
characteristics analysis. This permitted a 
statistically optimal cut-off value for FIT to be 
determined based on the maximisation of 
sensitivity and specificity. Clinicians and patients 
were blinded to the FIT results.
Results
In total, 5040 patients were fully evaluated and 
CRC was detected in 151 (3.0%). An optimal 
cut-off value of 19 µg Hb/g faeces for CRC 
was determined, giving a sensitivity of 85.4% 
(95% confidence interval [CI] = 78.8% to 90.6%) 
and specificity of 85.2% (95% CI = 84.1% to 86.2%). 
The negative predictive value at this cut-off value 
was 99.5% (95% CI = 99.2% to 99.7%) and the 
positive predictive value 15.1% (95% CI = 12.8% to 
17.7%). Sensitivity and specificity of FIT for CRC 
and significant premalignant polyps at this cut-off 
value were 62.9% (95% CI = 57.5% to 68.0%) and 
86.4% (95% CI = 85.4% to 87.4%), respectively; 
and when including all organic enteric disease 
were 35.7% (95% CI = 32.9% to 38.5%) and 88.6% 
(95% CI = 87.5% to 89.6%), respectively.
Conclusion
FIT used in patients fulfilling NG12 criteria 
should allow for a more personalised CRC risk 
assessment. FIT should permit effective, patient-
centred decision-making to inform the need for, 
type, and timing of further investigation.
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Additionally, the study sought to identify 
all clinically significant disease detected in 
those referred patients in order to obtain 




Ethical approval was obtained to conduct a 
prospective, blinded, multi-centre diagnostic 
accuracy study of FIT for clinical outcomes in 
patients referred with suspected CRC within 
the ‘2-week wait’ pathway from 25 April 
2018 to 31 December 2019. 
Participants
Twelve secondary care providers across 
Yorkshire and Humber were involved in 
this study. It was conducted following the 
standards for the reporting of diagnostic 
accuracy studies guidelines.17 A referral 
proforma containing the NG12 referral 
criteria was used by GPs to access the ‘2-week 
wait’. At each site, a convenience series 
of patients attending dedicated ‘2-week 
wait’ colorectal outpatient or telephone 
clinics were consented for the study by a 
research nurse. The ‘convenience’ related 
to the availability of the research nurse 
rather than any patient characteristics. 
Patient symptoms and relevant medical 
history were recorded. While GPs were 
guided by the NG12 referral criteria, to 
ensure that the study was representative 
of the population currently being referred, 
a formal assessment of compliance was 
deliberately not undertaken.
Test methods
The consenting process was independent 
of any decision by the responsible clinician 
to investigate the patient. Symptomatology, 
patient demographics, Index for Multiple 
Deprivation (IMD), use of non-steroidal 
anti-inflammatory drugs (NSAIDs), 
antiplatelet or anticoagulant therapy, 
relevant personal and family history, and 
baseline blood tests were recorded. The 
decision to investigate was made on clinical 
grounds at the discretion of the responsible 
clinician. Patients and clinicians were 
blinded to the FIT result throughout. Only 
patients undergoing full colonoscopy or 
CT colonography, or a lesser investigation 
(such as CT abdomen/pelvis with contrast 
or flexible sigmoidoscopy), were included 
in the data analysis.18 Relevant data and 
final diagnoses accessed from patient-
management systems were stored 
anonymously on an electronic case report 
form. Significant premalignant polyps are 
defined as adenomatous or hyperplastic 
lesions with high-grade dysplasia, or one 
≥10 mm in size or if there are a total 
of ≥5 subcentimetre polyps (excluding 
hyperplastic rectal polyps).19 OED includes 
IBD, microscopic colitis, radiation 
proctopathy, and those cases where the 
responsible clinician judged the referral 
diagnosis to be diverticular disease. IBD 
is reported separately from other OED in 
some statistical analysis. Asymptomatic, 
moderate diverticulosis, or that described 
as minor or mild was not included within 
OED. When no CRC, significant polyp, or 
OED diagnosis was made the diagnosis 
was reported as irritable bowel syndrome, 
haemorrhoidal bleeding, or iron deficiency 
(no cause found) as appropriate. For the 
purposes of the study this cohort has been 
grouped as ‘other functional diagnoses’.
FIT analysis
Consenting patients collected a single 
faecal sample using an EXTEL HEMO-
AUTO MC collection device between their 
out-patient consultation and subsequent 
investigation. FIT analysis was performed 
using an automated turbidometric system, 
HM-JACKarc. Calibration was performed 
in line with the manufacturer’s instructions, 
and internal quality control samples 
provided by the manufacturer were analysed 
in each batch. The analytical coefficient of 
variation (% CV) between batches was 4.6% 
at a concentration of 27 µg Hb/g faeces 
and 3.6% at a concentration of 102 µg 
Hb/g faeces. External quality assessment 
samples from UK NEQAS were analysed 
regularly. The manufacturer’s quoted 
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How this fits in 
The role of the faecal immunochemical 
test (FIT) in the assessment of patients 
at high risk of colorectal cancer (CRC) is 
uncertain. FIT has a high sensitivity and 
specificity for CRC with an area under 
the curve of 0.89. Some patients in whom 
FIT sufficiently alters their risk should no 
longer be investigated within the ‘2-week 
wait’ pathway. However, FIT is an imperfect 
diagnostic test for colorectal disease 
and will miss some currently referred 
patients, who have CRC, other significant 
premalignant polyps, inflammatory bowel 
disease, and other non-colorectal cancer. 
FIT should be used in all patients at high 
risk of CRC to inform the need for, type, and 
timing of further investigation. Studies are 
needed to understand how best to optimise 
the benefits of FIT in the clinical context 
of patients fulfilling National Institute for 
Health and Care Excellence guideline 12 
(NG12) referral criteria for suspected CRC.
limit of quantitation of 7 µg Hb/g faeces 
(imprecision <10% CV), analytical range of 
7–400 µg Hb/g faeces, and limit of detection 
of 2 µg Hb/g faeces were used in this study.
Sample size
Using an expected CRC incidence of 3%–5%, 
this study aimed to recruit a minimum 
of 5000 patients in order to achieve a 
representative sample for this diagnostic 
accuracy study.14
Statistical analysis
For the purposes of this study, the primary 
diagnostic accuracy analyses of FIT in 
detecting CRC and the secondary clinical 
outcomes were derived using receiver 
operating characteristics (ROC) curves. The 
point on the ROC curve that maximises 
both sensitivity and specificity was used 
to determine a statistically optimal cut-off 
value. Estimates of the area under the 
curve (AUC), sensitivity, specificity, and 
negative (NPV) and positive (PPV) predictive 
values were calculated (using the optimal 
cut-off value for the latter four measures) 
and presented alongside 95% confidence 
intervals (CIs). Since the optimisation of 
FIT may ultimately be determined by a 
composite of clinical factors beyond 
Youden’s index, the sensitivity, specificity, 
NPV, and PPV of FIT were also calculated 
for cut-offs of 2 (the limit of detection), 
10, 30, 100, and 300 µg Hb/g faeces. The 
proportion of disease cases versus non-




In total, 5153 patients were recruited 
(Figure 1 and Supplementary Table S1). The 
mean age was 67.4 (standard deviation 11.7) 
years and 2852 (55.3%) of the patients were 
female. The most common presenting 
symptoms were diarrhoea (n = 1872; 
36.3%), abdominal pain (n = 1746; 33.9%), 
and fresh rectal bleeding (n = 1721; 33.4%). 
Approximately 10% of patients had a family 
history of CRC, with 1389 (27.0%) using 
either antiplatelet therapy, anticoagulants, 
or NSAIDs (see Supplementary Tables S1 
and S2). Of the 5153 recruited patients, 113 
(2.2%) either declined or were not offered 
any formal investigations and were excluded 
from the primary and secondary analyses. 
Clinical and demographic details of those 
remaining 5040 patients with a primary 
or secondary outcome are presented in 
Supplementary Tables S3 and S4.
The most common investigations 
were colonoscopy (n = 3857; 76.5%), CT 
colonography (n = 751; 14.9%), and CT of the 
abdomen or pelvis (n = 1086; 21.5%) (see 
Supplementary Table S5). Final diagnoses 
were 3.0% CRC (n = 151), 4.1% significant 
premalignant polyps (n = 206), 2.0% IBD 
(n = 100), 15.3% OED (n = 771), 17.6% 
diminutive colorectal polyps (n = 682), 8.3% 
significant non-enteric disease (n = 418), 
and 53.8% other functional diagnoses 
(n = 2712).
Primary analysis 
Diagnostic accuracy of FIT for colorectal 
cancer. CRC was detected in 151 (3.0%) of the 
5040 patients evaluated. An optimal cut-off 
value of 19 µg Hb/g faeces was determined 
giving a sensitivity of 85.4% (95% CI = 78.8% to 
90.6%), a specificity of 85.2% (95% CI = 84.1% 
to 86.2%), a PPV of 15.1% (95% CI = 12.8% to 
17.7%), and an NPV of 99.5% (95% CI = 99.2% 
to 99.7%) (Table 1 and Supplementary 
Table S6). The AUC was estimated to be 0.89 
(95% CI = 0.86 to 0.92) (see Supplementary 
Figure S1). Using this threshold, 854 (16.9%) 
patients were considered to have a ‘positive 
FIT’, of whom 129 (85.4% of those with CRC) 
had CRC. By contrast, 4186 (83.1%) patients 
were considered to have a ‘negative FIT’ with 
22 (14.6% of those with CRC) having CRC. 
The location of the CRC, whether right-
sided, left-sided, or rectal did not alter the 
diagnostic accuracy of FIT. The sensitivity, 
specificity, PPV, and NPV of FIT for CRC at 
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 ‘2ww’ patients




received, n = 5153
Patients not
evaluated, n = 113
Patients declined
investigation, n = 80
Without formal
investigation to
diagnosis, n = 33
Patients









incorrectly, n = 49
Withdrew
consent, n = 18
‘Other’, n = 20
Figure 1. Flow of participants from attendance in 
2-week wait clinics for suspected CRC through to 
formal evaluation. 2WW = 2-week wait. 
CRC = colorectal cancer. FIT = faecal immunochemical 
test.
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five different fixed positivity thresholds from 
2–300 µg Hb/g faeces were determined, and 
the proportion of CRC based on different 
FIT ranges presented graphically (Table 2 
and Figure 2). An exploratory analysis of 
the tumour stage of the TNM Classification 
of Malignant Tumours was available for 
114 patients with CRC (see Supplementary 
Table S7). Of the 19 patients with CRC TNM 
staging and FIT ≤18 µg Hb/g faeces, 21.1% 
(n = 4) were T1, 31.6% (n = 6) T2, 26.3% (n = 5) 
T3, and 21.1% (n = 4) T4. 
Subgroup analyses: symptoms, 
demographics, and drugs. Subgroup 
analyses were performed across a range of 
demographics, symptoms, and the use of 
drugs to identify subgroup-specific FIT optimal 
cut-off values (Table 1 and Supplementary 
Table S6). There were no differences in the 
sensitivity of FIT in the subgroup analyses. 
However, the specificity of FIT differed in the 
following subgroups: change in bowel habit, 
constipation, abdominal pain, and drug use. 
Secondary analyses
Diagnostic accuracy of FIT for CRC, significant 
polyps, IBD, and all OED. In total, 342 (6.8%) 
patients had the secondary outcome of 
having either CRC or significant premalignant 
polyps, while 1147 (22.8%) had the secondary 
outcome of having either CRC, significant 
premalignant polyps, IBD, or OED (see 
Supplementary Table S7). The diagnostic 
accuracy of FIT in this setting was poorer, 
Table 1. Primary outcome analysis and subgroup analyses
  Cases,  Optimal  Sensitivity,  Specificity,  PPV, %  NPV, %  AUC 
 N n (%) cut-off, µg/g % (95% CI) % (95% CI) (95% CI) (95% CI) (95% CI)
Primary outcome




 <60 1217 30 (2.5) 37 90.0 (73.5 to 97.9)  87.4 (85.4 to 89.3)  15.3 (10.4 to 21.5)  99.7 (99.2 to 99.9)  0.92 (0.88 to 0.96)
 ≥60 3823 121 (3.2) 19 83.5 (75.6 to 89.6) 85.4 (84.2 to 86.5) 15.7 (13.0 to 18.8) 99.4 (99.0 to 99.6) 0.88 (0.85 to 0.92)
Sex        
 Male 2242 89 (4.0) 21 85.4 (76.3 to 92.0)  83.7 (82.0 to 85.2) 17.8 (14.3 to 21.7)  99.3 (98.8 to 99.6)  0.89 (0.86 to 0.93)
 Female 2798 62 (2.2) 16 87.1 (76.1 to 94.3) 85.6 (84.2 to 86.9) 12.0 (9.2 to 15.4) 99.7 (99.3 to 99.9) 0.88 (0.82 to 0.93)
Change in bowel habit
 Yes 3467 89 (2.6) 16 85.4 (76.3 to 92.0)  85.8 (84.5 to 86.9)  13.6 (10.9 to 16.8)  99.6 (99.2 to 99.8)  0.89 (0.85 to 0.93)
 No 1573 62 (3.9) 21 87.1 (76.1 to 94.3) 82.3 (80.2 to 84.2) 16.8 (12.9 to 21.3) 99.4 (98.7 to 99.7) 0.89 (0.84 to 0.93)
Rectal bleeding        
 Yes 1912 77 (4.0) 37 90.9 (82.2 to 96.3)  83.2 (81.4 to 84.8)  18.5 (14.7 to 22.7) 99.5 (99.1 to 99.8)  0.90 (0.87 to 0.93)
 No 3128 74 (2.4) 10 79.7 (68.8 to 88.2) 84.0 (82.6 to 85.3) 10.8 (8.3 to 13.7) 99.4 (99.0 to 99.7) 0.87 (0.82 to 0.92)
Abdominal pain        
 Yes 1722 47 (2.7) 10 85.1 (71.7 to 93.8) 82.5 (80.6 to 84.3)  12.0 (8.7 to 16.0) 99.5 (99.0 to 99.8)  0.88 (0.83 to 0.93)
 No 3318 104 (3.1) 37 85.6 (77.3 to 91.7) 88.4 (87.2 to 89.5) 19.2 (15.7 to 23.1) 99.5 (99.1 to 99.7) 0.90 (0.86 to 0.93)
Weight loss
 Yes 1093 38 (3.5) 13 89.5 (75.2 to 97.1)  83.1 (80.7 to 85.3)  16.0 (11.4 to 21.7)  99.5 (98.8 to 99.9)  0.88 (0.82 to 0.94) 
 No 3947 113 (2.9) 19 85.8 (78.0 to 91.7) 85.0 (83.8 to 86.1) 14.4 (11.9 to 17.3) 99.5 (99.2 to 99.7) 0.89 (0.86 to 0.93)
ID anaemiaa        
 Yes 559 34 (6.1) 21 82.4 (65.5 to 93.2)  81.5 (77.9 to 84.8)  22.4 (15.4 to 30.7)  98.6 (97.0 to 99.5) 0.87 (0.80 to 0.93)
 No 3582 101 (2.8) 19 88.1 (80.2 to 93.7) 85.3 (84.0 to 86.4) 14.8 (12.0 to 17.9) 99.6 (99.3 to 99.8) 0.90 (0.87 to 0.93)
aNumber of patients and cases do not add up to 5040 and 151, respectively, owing to missing anaemia and ID status. AUC = area under curve. ID = iron deficiency. NPV = negative 
predictive value. PPV = positive predictive value.
Table 2. Diagnostic accuracy of FIT in detecting the primary outcome 
of colorectal cancer at thresholds of 2, 10, 30, 100, and 300 µg Hb/g 
faeces
 Sensitivity,  Specificity,  PPV, %  NPV, % 
 % (95% CI) % (95% CI) (95% CI) (95% CI)
FIT ≥2 µg/g 92.7 (87.3 to 96.3) 60.7 (59.3 to 62.1) 6.8 (5.7 to 8.0) 99.6 (99.3 to 99.8)
FIT ≥10 µg/g 87.4 (81.0 to 92.3) 80.9 (79.7 to 81.9) 12.4 (10.4 to 14.5) 99.5 (99.3 to 99.7)
FIT ≥30 µg/g 80.1 (72.9 to 86.2) 87.7 (86.8 to 88.6) 16.8 (14.1 to 19.7) 99.3 (99.0 to 99.5)
FIT ≥100 µg/g 66.2 (58.1 to 73.7) 92.7 (91.9 to 93.4) 21.8 (18.1 to 25.8) 98.9 (98.5 to 99.2)
FIT ≥300 µg/g 53.0 (44.7 to 61.1) 95.1 (94.5 to 95.7) 25.2 (20.5 to 30.3) 98.5 (98.1 to 98.8)
FIT = faecal immunochemical test. NPV = negative predictive value. PPV = positive predictive value.
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and is presented both at the optimal cut-off 
value for each secondary analysis group 
and at 19 µg Hb/g faeces (Table 3). Here 717 
patients with secondary diagnoses (72.1%) 
were ‘FIT negative’. This represents 59.6% 
of the patients with significant premalignant 
polyps and 36.0% of the patients with IBD. 
The proportion of CRC or one of these 
secondary diagnoses based on the FIT 
range is presented graphically (Figure 3).
Opportunistic and non-enteric diagnoses. Of 
the 206 patients with significant premalignant 
polyps, only 43.0% had symptoms of rectal 
bleeding or rectal mass; the remainder 
should be considered opportunistic findings. 
A further 682 patients were found to have 
opportunistic, low-risk premalignant polyps, 
84.0% of whom had a FIT <19 µg Hb/g 
faeces. Significant non-enteric disease that 
required onward medical management 
was found in 418 (8.3%) additional patients, 
of whom 83 (19.9%) had non-colorectal 
cancers (see Supplementary Table S7). 
DISCUSSION
Summary
This diagnostic accuracy study, recruiting 
over 5000 patients in a convenience series, 
represents as closely as pragmatically 
possible the population of adults seen within 
primary care with symptoms judged to be 
high-risk for CRC. The IMD seen across the 
12 NHS Hospital Trusts in Yorkshire and 
Humber in this study broadly mirrors that in 
England overall, and includes a number of 
large conurbations with an ethnic diversity. 
Colonoscopy, CTC or flexible sigmoidoscopy 
and abdomino-pelvic CT were performed 
on 92.5% of patients.19 Only 33 patients 
were excluded from the evaluation as they 
underwent no secondary care investigation. 
This likely reflects the current clinical 
imperative of secondary care to investigate 
patients referred with suspected CRC. A 
statistically optimal cut-off value of 19 µg 
Hb/g faeces for CRC was determined using 
ROC curves, giving a sensitivity of 85.4% 
(95% CI = 78.8%  to 90.6%) and specificity 
of 85.2% (95% CI = 84.1% to 86.2%). The 
negative predictive value at this cut-off value 
was 99.5% (95% CI = 99.2% to 99.7%) and 
the positive predictive value was 15.1% (95% 
CI = 12.8% to 17.7%). 
Comparison with existing literature
Previous smaller diagnostic accuracy 
studies quoted a sensitivity for CRC of very 
close to 100% for FIT.20,21 Subsequently, it 
became clear that dependent on the cut-off 
Figure 2. Proportion of CRC at different FIT level (µg 
Hb/g faeces) ranges. Each data point represents the 
midpoint of consecutive FIT level ranges. Readings <2 
are represented by a value of 1 and readings of ≥400 
are represented by a value of 400. Line represents 
automatically fitted power trendline. CRC = colorectal 




































Table 3. Secondary outcome analyses
  Cases,  Optimal Sensitivity,  Specificity,  PPV, %  NPV, %  AUC 
 N n (%) cut-off, µg/g % (95% CI) % (95% CI) (95% CI) (95% CI) (95% CI)
Secondary outcomes        
CRC or SPP 5040 342 (6.8) 7 69.6 (64.4 to 75.4) 78.9 (77.7 to 80.0) 19.3 (17.2 to 21.7) 97.3 (96.7 to 97.8) 0.79 (0.76 to 0.82)
CRC, SPP, or IBDa 5040 442 (8.8) 6 69.9 (65.4 to 74.2) 78.6 (77.4 to 79.8) 23.9 (21.6 to 26.4) 96.5 (95.8 to 97.0) 0.80 (0.77 to 0.82)
CRC, SPP, IBD, or OED 5040 1147 (22.8) 2 56.7 (53.7 to 59.6) 63.8 (62.2 to 65.3) 31.6 (29.5 to 33.6) 83.3 (81.9 to 84.6) 0.64 (0.62 to 0.66)
Diagnostic accuracy of FIT in detecting each secondary outcome using a cut-off of 19 µg Hb/g faeces
CRC or SPPa    62.9 (57.5 to 68.0) 86.4 (85.4 to 87.4) 25.2 (22.3 to 28.2) 97.0 (96.4 to 97.5) —
CRC, SPP, or IBDa    63.1 (58.4 to 67.6) 87.5 (86.5 to 88.4) 32.7 (29.5 to 35.9) 96.1 (95.5 to 96.7) —
CRC, SPP, IBD, or OEDa    35.7 (32.9 to 38.5) 88.6 (87.5 to 89.6) 47.9 (44.5 to 51.3) 82.4 (81.1 to 83.5) —
aExploratory analysis. AUC = area under curve. CRC = colorectal cancer. FIT = faecal immunochemical test. IBD = inflammatory bowel disease. NPV = negative predictive value. 
OED = organic enteric disease. PPV = positive predictive value. SPP = significant premalignant polyps.
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chosen, FIT will miss between 7% and 15% 
of patients with CRC.22–24 The sensitivity and 
specificity of FIT for CRC in this study aligns 
with the smaller studies that recruited 
patients fulfilling NG12 criteria.16,25 The 
authors’ previous study determined the 
optimal cut-off value for FIT to be ≥12 µg 
Hb/g faeces. In that study, however, faecal 
sampling into collection devices was 
performed in the laboratory instead of by the 
patient and this may have resulted in some 
pre-analytic haemoglobin degradation.26,27 
The published study most comparable by 
design — since it too recruited patients 
exclusively referred through the ‘2-week 
wait’ for CRC and used an HM-JACKarc 
analyser — found a similar sensitivity and 
specificity of 84% and 93%, respectively.25 In 
Scotland, where the Scottish Intercollegiate 
Guidance Network guidance produces a 
different referral population from NICE, 
FIT has a similar diagnostic accuracy to 
this study.21,28–30 A similar sensitivity and 
specificity are obtained in the two other 
large diagnostic accuracy studies that have 
been conducted in England: the NICE FIT 
study and the qFIT pilot study. The recently 
published NICE FIT study reports an AUC 
for CRC of 0.93 (95% CI = 0.92 to 0.95) and 
an optimal cut-off value for FIT of 38 µg 
Hb/g faeces.31,32
Strengths and limitations
This diagnostic accuracy study presents 
its findings in terms of the statistical 
optimisation of the sensitivity and specificity 
of FIT. The use of a statistically optimal 
cut-off value highlights the need for FIT to 
be considered as a tool by which to both 
minimise the risk of missing CRC, and to 
optimise the use of investigative resource 
within a constrained healthcare system. 
There is an inevitable trade-off between the 
two. Reconciling that trade-off is a major 
healthcare challenge. Ultimately, a detailed 
and comprehensive health economic 
analysis is required to determine the true 
clinical utility of FIT. This is beyond the 
scope of this study; however, recognising 
the complexity of this task, the data have 
also been presented with a range of cut-off 
values: 2 (the limit of detection), 10, 30, 100, 
and 300 µg Hb/g faeces. 
Very little is yet known about the 
response of symptomatic patients and their 
clinicians to a FIT-based assessment, and 
the savings of investigative resource that 
might result. Therefore, it was deemed that 
using a statistical measure represented 
the appropriate starting point for that 
risk analysis. Using this approach, a high 
sensitivity and specificity for FIT is retained 
across age and sex, symptoms and signs, 
medicines use, and anaemia. The optimal 
cut-off value for people aged ≥60 years 
(19 µg Hb/g faeces) is lower than for those 
aged <60 years (37 µg Hb/g faeces), and 
is lower for females (16 µg Hb/g faeces) 
than for males (21 µg Hb/g faeces).16,33–35 
Interestingly, and contrary to NICE 
diagnostics guidance 30 (DG30), it was found 
that FIT retained a high diagnostic accuracy 
in those with rectal bleeding, although the 
optimal cut-off value was higher in those 
with (37 µg Hb/g faeces) than without (10 µg 
Hb/g faeces) bleeding. It had previously 
been the authors’ experience with faecal 
calprotectin that the diagnostic accuracy 
of a faecal biomarker was preserved in 
the context of rectal bleeding.36 It was 
speculated that anal canal bleeding might 
coat rather than impregnate the faeces, 
and thereby not interfere with sampling 
from the centre of a formed faecal sample. 
Previous studies have also suggested that 
the diagnostic accuracy of FIT is lower in 
patients with anaemia, but this was not 
found to be the case in iron deficiency or 
iron deficiency anaemia.21,23 In line with the 
qFIT pilot study, the optimal cut-off value for 
those patients with abdominal pain was set 
lower at 10 µg Hb/g faeces.32 Lastly, only in 
the small subgroup of patients who had an 
abdominal mass did FIT achieve a sensitivity 
of 100% (see Supplementary Table S6). 
Otherwise, FIT inevitably misses CRC in 
a small number of patients. Alternative 
approaches to using FIT — such as applying 
the lowest possible cut-off — either the 
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Figure 3. Proportion of disease cases (CRC with 
significant premalignant polyps, IBD and all OED) at 
different FIT level (µg Hb/g faeces) ranges. 
Each data point represents the midpoint of consecutive 
FIT level ranges. Readings <2 are represented by a 
value of 1 and readings of ≥400 are represented by 
a value of 400. Lines represent automatically fitted 
power trendlines. CRC = colorectal cancer. FIT = faecal 
immunochemical test. IBD = inflammatory bowel 
disease. OED = organic enteric disease.
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the limit of detection (2 µg Hb/g faeces) are 
unlikely to be effective in preventing missed 
CRC. They will improve the NPV of FIT by 
0.1% at the cost of an inferior PPV, and so 
will more than double the burden imposed 
on investigative resource. This trade-off 
also applies at the cut-off value 10 µg Hb/g 
faeces, as currently recommended by NHS 
England in its specialty guides for patient 
management during the coronavirus 
pandemic.37 The imperfect nature of FIT at 
whatever cut-off value chosen reinforces 
the need for a formal, contextualised health 
economic analysis to determine a clinically 
— rather than necessarily statistically — 
optimal FIT cut-off value.38
Implications for practice
Whatever acceptable balance of risk is 
ultimately arrived at, the authors believe 
that FIT must primarily be used to 
‘democratise’ the CRC risk assessment.39 
In future, a personalised, optimal FIT cut-
off value can be generated as a ‘risk score’ 
for an individual patient, based on sex, age, 
symptoms and signs, drug history, and 
blood parameters. GP electronic requesting 
systems can be used to capture clinical 
indications for FIT requests, and this can 
be linked together with demographic data, 
other blood results, and FIT results in the 
laboratory information system. These data 
could be used in future by an automated 
algorithm to generate a personalised risk 
score to accompany or replace the numerical 
FIT result, and this risk score could then be 
reported along with recommendations on 
referral or management based on it.
That personalised CRC risk next needs 
to be incorporated into a personalised 
clinical assessment of the patient. This is 
the challenge. This study demonstrates 
that ‘FIT negative’ patients with NG12 
criteria for suspected CRC have a CRC 
risk <0.5%. This may be lower than the 
prevalent risk of CRC in an equivalently aged 
asymptomatic population.40,41 But more 
than one in five of the patients referred had 
an OED that required prompt diagnosis and 
management, even if not within the ‘2-week 
wait’ timeframe. This included 14.2% of the 
‘FIT negative’ patients, such as those with 
IBD, where early diagnosis has been shown 
to minimise complications and the need 
for surgery.42,43 In addition, another 8.3% of 
patients had significant non-enteric disease, 
including other cancers such as ovarian, 
pancreatic, and renal cancer. In total, non-
CRC malignancies accounted for 35.5% 
of all the cancer diagnoses in this study.44 
The opportunistic diagnosis of diminutive 
premalignant colorectal polyps represents 
a further cohort, currently undefined, of 
screening benefit for the population. Lastly, 
many of those with ongoing functional 
symptoms and haemorrhoidal bleeding will 
remain symptomatic within a population 
previously considered high-risk for CRC. 
In England, initial symptomatic treatment 
strategies are not currently offered in 
these patients, as they are in Scotland.45–48 
While only 16.9% of ‘2-week wait’ patients 
referred in this study had a ‘positive FIT’, 
this will not represent the proportion of 
patients ultimately referred to secondary 
care in any future FIT-based pathway. The 
authors have previously estimated that 25% 
might be spared investigation by the use 
of a faecal biomarker and the resolution of 
symptoms.49 
FIT can reduce CRC risk well below the 
3% threshold on which the NG12 guidelines 
were devised. However, it is not currently 
known what alternative management 
strategies are required to support optimal 
patient and clinician decisionn making 
on the need for, type, and timing of 
investigations.50–53 Investigation is not risk 
free, and for many frail patients that risk 
will now exceed any benefit that could be 
derived from early diagnosis of disease.54,55 
If FIT could spare unnecessary investigation 
and redirect resource to other diagnostic 
pathways such as the BCSP, there could 
be a net significant health economic benefit 
for the wider population.9–11 Those NG12 
patients with CRC missed because of 
a ‘negative FIT’ would be offset by the 
increased number of detected participants 
with CRC in the BCSP. FIT has a high 
diagnostic accuracy for CRC, and should 
be used in the clinical assessment of all 
patients fulfilling the NICE NG12 criteria 
for suspected CRC.37,55,56 Patients in whom 
FIT sufficiently alters that risk assessment 
should no longer be investigated within the 
‘2-week wait’. However, it is important to 
recognise that FIT will miss some patients 
with CRC, OED, and non-gastrointestinal 
pathology currently identified using NG12 
criteria. FIT allows for a redesign of the 
current, largely symptom-based, referral 
process defined in NG12 into a novel, risk-
based decision-making pathway for the 
care for patients with abdominal symptoms. 
If properly developed and applied, the net 
benefit of using FIT as an alternative to 
symptom-based referral criteria could be 
the optimised early diagnosis of CRC, and 
reduced morbidity and mortality for the 
whole population.
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